TD Private Client Wealth’s GSK GSK Stock Holding History

TD Private Client Wealth’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$506K	Sell	9,645 -3,065	-24%	-$162K	0.01%	500
2026 Q1	$701K	Sell	12,710 -58,077	-82%	-$3.15M	0.01%	423
2025 Q4	$3.47M	Sell	70,787 -16,404	-19%	-$765K	0.07%	174
2025 Q3	$3.76M	Buy	87,191 +9,172	+12%	+$358K	0.08%	162
2025 Q2	$3M	Buy	78,019 +70,910	+997%	+$2.71M	0.07%	191
2025 Q1	$275K	Buy	7,109 +4,383	+161%	+$160K	0.01%	543
2024 Q4	$92.2K	Sell	2,726 -9,696	-78%	-$349K	﹤0.01%	727
2024 Q3	$508K	Buy	12,422 +3,346	+37%	+$137K	0.01%	455
2024 Q2	$349K	Buy	9,076 +26	+0.3%	+$1.09K	0.01%	489
2024 Q1	$388K	Buy	9,050 +1,768	+24%	+$72.9K	0.01%	481
2023 Q4	$270K	Sell	7,282 -159	-2%	-$5.71K	0.01%	512
2023 Q3	$270K	Sell	7,441 -5,735	-44%	-$204K	0.01%	497
2023 Q2	$470K	Buy	13,176 +4,071	+45%	+$146K	0.02%	448
2023 Q1	$324K	Buy	9,105 +6,796	+294%	+$238K	0.01%	481
2022 Q4	$81.1K	Sell	2,309 -14,111	-86%	-$470K	﹤0.01%	656
2022 Q3	$483K	Buy	16,420 +1,151	+8%	+$43.6K	0.02%	408
2022 Q2	$831K	Buy	15,269 +1,043	+7%	+$57.6K	0.04%	344
2022 Q1	$775K	Buy	14,226 +4,889	+52%	+$266K	0.03%	368
2021 Q4	$515K	Buy	9,337 +3,511	+60%	+$183K	0.02%	415
2021 Q3	$278K	Sell	5,826 -1,496	-20%	-$75.1K	0.01%	483
2021 Q2	$364K	Sell	7,322 -1,464	-17%	-$70.3K	0.02%	445
2021 Q1	$392K	Sell	8,786 -12,827	-59%	-$582K	0.02%	426
2020 Q4	$994K	Sell	21,613 -63,107	-74%	-$2.9M	0.05%	302
2020 Q3	$3.99M	Sell	84,720 -10,487	-11%	-$525K	0.22%	100
2020 Q2	$4.85M	Sell	95,207 -18,722	-16%	-$961K	0.28%	73
2020 Q1	$5.4M	Buy	+113,929	New	+$6.08M	0.39%	57

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

TD Private Client Wealth's GSK Position: Q2 2026 in Review

TD Private Client Wealth reduced its GSK (GSK) stake by 24% in Q2 2026, selling an estimated $162K and leaving 9,645 shares worth $506K. The position accounts for 0.01% of the portfolio, ranked #500.

TD Private Client Wealth first reported a position in GSK in Q1 2020 and has held it in 26 quarters since. The position peaked at $5.4M in Q1 2020. 1,039 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

TD Private Client Wealth held 9,645 shares of GSK worth $506K as of Q2 2026.
TD Private Client Wealth sold 3,065 GSK shares in Q2 2026, an estimated $162K.
GSK made up 0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #500 holding.
TD Private Client Wealth first reported a position in GSK in Q1 2020 and has held it in 26 quarters since.
TD Private Client Wealth's GSK position peaked at $5.4M in Q1 2020.
1,039 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.